Carbon Linker Variants
Carbon Linker Variants - Related Videos
14:40
Expression Analysis of Mammalian Linker-histone Subtypes
0 Views •
Cited by 22 •
2012
We describe a set of assays to analyze expression levels of H1 linker histones. mRNA of individual H1 genes are quantitatively measured by random primer based reverse transcription followed by real-time PCR, whereas protein quantification of H1 histones is achieved by HPLC analysis.
10:34
Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR
0 Views •
Cited by 3 •
2013
A method of identifying unknown drivers of carcinogenesis using an unbiased approach is described. The method uses the Sleeping Beauty transposon as a random mutagen directed to specific tissues. Genomic mapping of transposon insertions that drive tumor formation identifies novel oncogenes and tumor suppressor...
01:09
Cytoskeletal Linker Proteins - Plakins
0 Views •
2023
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
02:30
Histone Variants at the Centromere
0 Views •
2020
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...
03:20
Generation of Influenza Virus Escape Variants against Neutralizing Antibodies
0 Views •
2025
This video demonstrates a technique for generating escape variants of neutralizing influenza virus monoclonal antibodies. Antibody-neutralized virus suspension is injected into embryonated chicken eggs to propagate escape variants selectively. This results in a virus population predominantly of escape variants, confirmed via a Hemagglutination assay.
FAQs
Changing linker length alters the distance and orientation between pharmacophores, the functional groups that contribute to molecular recognition. A shorter or longer spacer can improve how those groups occupy a binding site, influencing target affinity and selectivity. Comparing length variants therefore helps researchers determine which three-dimensional arrangement best supports the desired pharmacological response.
Branching changes the shape and steric environment of a molecule, while flexibility changes how many conformations it can adopt. These features can alter the presentation of binding groups and affect affinity, selectivity, lipophilicity, metabolic stability, and membrane permeability. Evaluating both properties helps distinguish whether activity depends on a precise geometry or adaptable molecular arrangement.
Introducing a ring structure can change the three-dimensional organization and conformational behavior of the connected pharmacophores. This may produce a different balance of target recognition, selectivity, lipophilicity, metabolic stability, and membrane permeability than a more flexible spacer. Such comparisons are useful when researchers seek a compound profile that supports efficacy while limiting undesirable pharmacological properties.
Researchers compare compounds that retain the relevant functional groups while varying linker length, branching, flexibility, or ring structure. They then relate these structural changes to differences in target affinity, selectivity, lipophilicity, metabolic stability, and membrane permeability. This organized comparison reveals structure–activity relationships and identifies linker features associated with improved pharmacological profiles.
They are especially useful when an early lead has promising activity but an unsuitable balance of pharmacological properties. Systematically modifying the spacer can help optimize target engagement alongside selectivity, lipophilicity, metabolic stability, and membrane permeability. The resulting comparisons guide selection of candidates with improved pharmacokinetic and pharmacodynamic profiles for further development.
Linker design allows researchers to tune how pharmacophores are positioned and how the resulting molecule behaves in biological settings. A favorable variant may preserve or improve target affinity while refining selectivity, permeability, lipophilicity, or metabolic stability. These changes support target-probe design and can contribute to therapeutic candidates with more effective and potentially safer pharmacological profiles.